Copper for Micronutrient Deficiency

Verdict: Effective for diagnosed copper deficiency, not prevention

For people with documented copper deficiency, copper repletion reliably reverses the blood-related abnormalities (anemia and low neutrophils), making it standard clinical care; the nerve damage it can cause is often only partly reversible, and healthy adults eating a balanced diet do not need to supplement.

A 🔵 A Moderate Evidence Published

🔬Why this grade7-layer evidence engine

This earns a moderate grade because the evidence is consistent but built almost entirely on retrospective case series and a case-report systematic review rather than randomized trials. A pooled review of 116 cases (PMID 33448718) found severe anemia and near-universal neutropenia that resolved within weeks of copper repletion, while a national review of 16 patients (PMID 23034053) reported cytopenia resolution in 93%. Smaller series (PMID 18284630, PMID 15834043) confirm the same prompt hematologic recovery.

The grade is held back from the top tier by a clear limitation: the neurologic damage (myeloneuropathy) responds poorly. In the same 16-patient review only 25% improved neurologically and 33% worsened, and the 116-case review concluded myelopathy may be irreversible, making early diagnosis the decisive factor. For inherited Menkes disease, copper-histidine helps only if started within roughly four weeks of birth (PMID 8229500); a delayed-treatment cohort saw 58% die before age five (PMID 24919650).

Regulators (FDA, EFSA, WHO) treat copper purely as an essential nutrient with no disease-treatment claims, and the UK NHS notes a varied diet supplies all the copper most people need. The clinical case is narrow and well-supported: post-bariatric reviews show routine multivitamin-mineral supplements cut deficiency from 10-18% to 0-5% (PMID 27034062, PMID 25271186, PMID 41353140). The strongest practical message is to watch for high-dose zinc, an often-overlooked, preventable cause of copper deficiency.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.73
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published
Confidence
84%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L5 Clinical bodiesAuthoritative stance
0.72
L11 AI re-checkIndependent read
0.80
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.727
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (9)L2 · primary research & systematic reviews

Hematological manifestations of copper deficiency: a retrospective review (Halfdanarson et al., Eur J Haematol)
PMID: 18284630 2008 Other n = 40
Finding: Anemia and neutropenia were the most common hematologic abnormalities; bicytopenia with normal platelets characteristic. Risk factors: 25% prior bariatric surgery, 35% other GI surgery, 30% idiopathic. Bone marrow showed vacuolated myeloid precursors, iron-containing plasma cells, ring sideroblasts. Hematologic findings responded promptly to copper repletion but coexisting myeloneuropathy often only partially reversed.
Academic
View on PubMed
Hypocupremia associated cytopenia and myelopathy: a national retrospective review (Spain et al., QJM/Scotland national lab)
PMID: 23034053 2013 Other n = 16
Finding: 86% had both hematologic and neurologic features; 75% had elevated serum zinc and 9 used zinc-containing denture adhesive. After copper repletion, 93% (15/16) had cytopenia resolution, but only 25% had neurologic improvement; 33% deteriorated neurologically and 42% remained unchanged. Authors stress early diagnosis to prevent irreversible spinal cord injury.
Academic Effect size: [object Object]
View on PubMed
Copper Deficiency and Cytopenias
PMID: 33448718 2021 系統性回顧 n = 116
Finding: 116 cases pooled. Median age 44 (IQR 25-57); 55% male. Median Hb 7.7 g/dL (6.2-9.5), median WBC 2.3 (1.6-3.1); 81% had Hb<10, 35% severe anemia (Hb<7); 69% had leukopenia, 98.7% with neutropenia. 32% had coexisting neurologic symptoms. Authors conclude anemia and neutropenia resolve within weeks after copper repletion, whereas myelopathy may be irreversible — establishing the differential reversibility paradigm.
🟢 High quality Academic Effect size: [object Object]
View on PubMed
Copper Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review (Gletsu-Miller et al., Obes Surg)
PMID: 27034062 2016 系統性回顧
Finding: Reported RYGB-associated copper deficiency prevalence 10-12% within 3 years, up to 18.8% in some series; with routine multivitamin-mineral supplementation deficiency falls to 0-5%. Concludes copper deficiency in adequately supplemented patients is rare and easily treated when diagnosed, but delays risk permanent neurologic deficit. Supports selective screening of high-risk groups rather than universal monitoring.
🟢 High quality Academic Effect size: [object Object]
View on PubMed
Incidence and prevalence of copper deficiency following roux-en-y gastric bypass surgery (Gletsu-Miller et al., Int J Obes)
PMID: 41353140 2025 Cohort n = 152
Finding: Prevalence 9.6% (13/136); incidence 18.8% (3/16) over 24 months. Plasma copper fell 10.8% at 6 mo (p=0.03) and 10.1% at 24 mo (p=0.04); ceruloplasmin activity fell 18.6% by 24 mo (p=0.016). Associated complications: anemia 46%, leukopenia 15%, neuropathy 38%, fatigue 38%. Supports routine Cu screening and supplementation as standard post-RYGB practice.
🟢 High quality Academic Effect size: [object Object]
View on PubMed
Copper, selenium and zinc levels after bariatric surgery in patients recommended to take multivitamin-mineral supplementation (Gehrer et al., J Trace Elem Med Biol)
PMID: 25271186 2015 Cohort n = 437
Finding: With routine MVM supplementation, copper deficiency prevalence stayed minimal: 2% preop, 0-5% postop with no significant change in median Cu (p=0.68). Selenium worsened (2% to 11-15%, p=0.056); zinc 7% to 7-15% (p=0.39). Confirms adequate supplementation maintains Cu status across the first 3 years post-bariatric surgery.
🟢 High quality Academic Effect size: [object Object]
View on PubMed
Copper deficiency myeloneuropathy and pancytopenia secondary to overuse of zinc supplementation (Prodan et al., J Neurol Neurosurg Psychiatry)
PMID: 15834043 2005 Other n = 4
Finding: Four patients with myeloneuropathy and pancytopenia traced to chronic zinc excess (denture cream, supplements). After Cu repletion + Zn withdrawal, all four normalized serum Cu and resolved pancytopenia within weeks; neurologic deficits stabilized or partially improved but residual sensory ataxia persisted. Established excess Zn from denture adhesives as a recognized acquired Cu-deficiency etiology.
Academic Effect size: [object Object]
View on PubMed
Copper-histidine therapy for Menkes disease (Sarkar et al., J Pediatr)
PMID: 8229500 1993 Other n = 7
Finding: 2/7 patients in whom Cu-histidine started within 1 month of birth had near-normal neurologic outcomes at 16 and 6 years; 5/7 patients started at 2-7 months did poorly despite treatment. Established the early-treatment-window principle for Menkes disease and Cu-histidine as effective only when initiated very early (ideally <4 weeks of life).
Academic Effect size: [object Object]
View on PubMed
Novel mutations and clinical outcomes of copper-histidine therapy in Menkes disease patients (Lee et al., Brain Dev)
PMID: 24919650 2015 Cohort n = 12
Finding: Despite Cu-histidine therapy 7/12 died before age 5; remaining 5 had severe neurodevelopmental delay. Outcomes attributed to delayed initiation (most diagnosed ~4 months) and severe ATP7A loss-of-function mutations. Reinforces that early (neonatal) initiation is necessary but not sufficient; mutation severity also dictates response.
Academic Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
Copper ... 0.9 mg source↗
L4b EU EFSA
Supportive
contributes to maintenance of normal connective tissues; contributes to normal functioning of the nervous system; contributes to normal cognitive function source↗
L4c UK NHS
Cautious
You should be able to get all the copper you need by eating a varied and balanced diet. source↗
L4d TW TFDA / 衛福部
Supportive
形態屬膠囊狀、錠狀且標示有每日食用限量之食品,在每日食用量中,其銅含量不得高於8毫克。限於補充食品中不足之營養素時使用。 source↗
L4e WHO
Neutral
A health-based guideline value of 2 mg/litre has been derived for copper in drinking-water... Copper is both an essential nutrient and a drinking-water contaminant. source↗
L5a NIH Office of Dietary Supplements
Supportive
Copper, an essential mineral, is naturally present in some foods and is available as a dietary supplement. It is a cofactor for several enzymes (known as 'cuproenzymes') involved in energy production, iron metabolism, neuropeptide activation, connective tissue synthesis, and neurotransmitter synthesis. source↗
L5b Mayo Clinic
Supportive
L5c Cleveland Clinic
Neutral
L5d Harvard Health
Neutral
L5e Specialty Society (condition-mapped)
Supportive
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬9 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-micronutrient-deficiency-INT-copper-001 繁體中文版 →